2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 289

Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 55

Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 475

Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 733

Advanced Chronic Kidney Disease in Lupus Nephritis: Factors Leading to Progression

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 590

Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 269

Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 86

Age Dependent Effects of Cholesterol and Smoking on the Risk of Rheumatoid Arthritis in Women – Results from a Nested Case Control Study

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 492

All Site Cancers and Lymphoma Incidence in US Veterans with Rheumatoid Arthritis 2001-2015

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 39

Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 136

Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 72

Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 710

An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 576

An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 190

An Innovative Pilot Educational Program to Inform Rheumatology Fellows about the Population of the Bronx: Issues Affecting and Resources Available to the Community

Education Poster

9:00AM-11:00AM: Abstract Number: 120

An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].